Amgen Inc. $AMGN Position Cut by Pacer Advisors Inc.

Pacer Advisors Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 22.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,257,213 shares of the medical research company’s stock after selling 355,908 shares during the quarter. Pacer Advisors Inc. owned about 0.23% of Amgen worth $411,498,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Investment Insight Wealth Management LLC bought a new position in shares of Amgen during the fourth quarter worth about $205,000. Monetary Solutions Ltd bought a new stake in Amgen in the 4th quarter valued at about $118,000. Walser Wealth Management Company A Ltd Liability Co bought a new stake in Amgen in the 4th quarter valued at about $528,000. MV Capital Management Inc. acquired a new position in Amgen during the 4th quarter valued at about $2,907,000. Finally, Sunbelt Securities Inc. boosted its stake in Amgen by 6.1% during the 4th quarter. Sunbelt Securities Inc. now owns 7,546 shares of the medical research company’s stock valued at $2,470,000 after purchasing an additional 432 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on AMGN shares. Truist Financial raised their price target on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Royal Bank Of Canada boosted their price objective on Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Wells Fargo & Company increased their price objective on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Jefferies Financial Group initiated coverage on Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. Finally, The Goldman Sachs Group set a $389.00 target price on Amgen in a research report on Friday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $354.42.

Amgen Stock Down 1.2%

Amgen stock opened at $337.60 on Friday. The stock has a market cap of $182.21 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 3.43 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company’s 50-day moving average price is $340.96 and its two-hundred day moving average price is $345.81. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts expect that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.